Related Experiment Video
Updated: Aug 12, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 31, 2013
[Immunotherapy of metastatic renal cell cancer]
1Klinik und Poliklinik für Urologie Medizinische Akademie Dresden Carl Gustav Carus.
Abstract:
In the treatment of advanced renal cell carcinoma, cytokines such as interferons, interleukin-2, tumor necrosis factor and immune therapy with autologous tumor cells and tumor cell vaccines have been tested on a large scale. A definitive cure of a patient with advanced renal cell cancer treated with cytokines or immune therapy has so far not been reported in the literature. The rates of objective remissions (PR and CR) are disappointing and rarely exceed 20% overall. The combination of interferon-alpha and interleukin-2 administered subcutaneously seems to offer the best results with the lowest morbidity. However since standard treatment protocols do not exist, treatment of patients with renal cell carcinoma using these substances should only be performed in prospective trials. Immunotherapy with interferons, interleukin-2, tumor necrosis factor, autologous tumor cells or tumor cell vaccines has to be regarded as experimental.
More Related Videos
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy

